All In Biotech

Drug Trial Radar · NCT03970837

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs

Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,764 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,764

Actual

Start

Jun 5, 2019

Primary completion

Oct 29, 2021

Study completion Jan 18, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study \[contRAst 2 (201791: NCT03970837)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to csDMARD(s) or bDMARD(s). The study will consist of a screening phase of up to 6 weeks followed by a 52 week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with csDMARD(s). Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165 may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • GSK3196165 (Otilimab)Biological

    GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

  • TofacitinibDrug

    Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.

  • PlaceboDrug

    Placebo matching GSK3196165 and Tofacitinib was administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo (Global Cohort)Time frame: Week 12
  2. Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 (Asia Cohort)Time frame: Week 12

Locations

269 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Tustin, California

  • GSK Investigational Site

    Van Nuys, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Fort Collins, Colorado

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Margate, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    New Port Richey, Florida

  • GSK Investigational Site

    Palmetto Bay, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

  • GSK Investigational Site

    Tamarac, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Idaho Falls, Idaho

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Bowling Green, Kentucky

  • GSK Investigational Site

    Lake Charles, Louisiana

  • GSK Investigational Site

    Monroe, Louisiana

  • GSK Investigational Site

    Hagerstown, Maryland

  • GSK Investigational Site

    Worcester, Massachusetts

  • GSK Investigational Site

    Grand Blanc, Michigan

  • GSK Investigational Site

    Lansing, Michigan

  • GSK Investigational Site

    Novi, Michigan

  • GSK Investigational Site

    Freehold, New Jersey

  • GSK Investigational Site

    Albuquerque, New Mexico

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.